AstraZeneca: Leukemia, Myeloid, Acute trials
The registry lists 13 Leukemia, Myeloid, Acute studies with AstraZeneca as lead sponsor. 1 are open to participants now and 2 have results posted.
Phase 1 12Phase 2 3Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX OverexpressionRecruitingNCT07155226Phase 1/2
- Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) PatientsCompletedNCT00952588Phase 2/3Results posted
- Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)TerminatedNCT00486265Phase 1Results posted
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.TerminatedNCT03218683Phase 1
- Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.TerminatedNCT03217838Phase 1
- A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological MalignanciesCompletedNCT03106428Phase 1
- Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) PatientsTerminatedNCT01489722Phase 1
- An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)CompletedNCT01019161Phase 1
- Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)CompletedNCT00926731Phase 1
- Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)CompletedNCT00530699Phase 1
- Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00497991Phase 1
- Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid LeukemiaCompletedNCT00086099Phase 1/2